R&D | Cutting-edge science and innovative research

News

ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).

News

ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer

New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforces earlier results in platinum-resistant ovarian cancer.

News

ESMO26: Halda buy delivers a win for J&J in prostate cancer

A drug at the heart of Johnson & Johnson's $3bn takeover of Halda has been shown to be "highly active" in a first-in-human prostate cancer trial.

News

ESMO26: BMS dual-acting ADC beats chemo in breast cancer

BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.

News

ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer

Two drugs hoping to muscle in on Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new trial readouts at ESMO.

R&D

Think global, act local: rethinking commercialisation models

The global market for life sciences is changing rapidly.

R&D

Amplifying the voices in rare diseases

There are approximately 300 million people around the world living with a rare disease. Yet, until relatively recently, there was limited focus on this heterogenous population.

News

Pfizer's seeks silver lining in failed C. diff vaccine trial

Pfizer's vaccine for Clostridium difficile (C.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).

News

ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer

New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforces earlier results in platinum-resistant ovarian cancer.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Wooden pawns on top of wooden block named BOARD

Changing Faces: Board of Director and Advisory Board hires, ...

September’s boardroom moves brought seasoned pharma executives, investors, and scientific leaders into new governance and advisory roles across the life sciences sector.

R&D

Digital box and pills, supply chain concept for pharma

From reactive to predictive: How data is redefining pharma l...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight.

R&D

Depressed woman looks out rain spattered window in city

Removing barriers in treatment-resistant depression

pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Boosting biotech in Basel – with Valentina Francia

pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.